This topic contains a solution. Click here to go to the answer

Author Question: Describe megakaryocyte development and the role of endomitosis and thrombopoietin in this process. ... (Read 32 times)

pragya sharda

  • Hero Member
  • *****
  • Posts: 566
Describe megakaryocyte development and the role of endomitosis and thrombopoietin in this process.
 
  What will be an ideal response?

Question 2

Which of the following best describes the role of platelet factor 4?
 
  a. Stimulates platelet aggregation
  b. Contributes to fibrin formation
  c. Neutralizes heparin
  d. Acts as a mitogenic factor



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

medine

  • Sr. Member
  • ****
  • Posts: 344
Answer to Question 1

Answer: Platelets develop from megakaryocytes. Megakaryocyte maturation is produced through endomitosis, which is different from mitosis because telophase is missing. As a result, nuclear duplication occurs without nuclear or cytoplasmic division. The resulting maturing cells are larger than in the previous stage. MK1 is smaller than MK2, which is smaller than MK3, which is smaller than MK4. The stages are very large (can reach up to 150 mcM), and can be easily spotted under low power when examining bone marrow specimens. These platelets respond to changes in thrombopoietin. Thrombopoietin interacts with c-MPL receptor on the megakaryocytes to induce thrombopoiesis and speed up the maturation time of the megakaryocyte. Mature platelets bud off the megakaryocyte and enter the circulation.

Answer to Question 2

Correct Answer: C




pragya sharda

  • Member
  • Posts: 566
Reply 2 on: Jun 25, 2018
Excellent


atrochim

  • Member
  • Posts: 331
Reply 3 on: Yesterday
Gracias!

 

Did you know?

Anti-aging claims should not ever be believed. There is no supplement, medication, or any other substance that has been proven to slow or stop the aging process.

Did you know?

Lower drug doses for elderly patients should be used first, with titrations of the dose as tolerated to prevent unwanted drug-related pharmacodynamic effects.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

Approximately 70% of expectant mothers report experiencing some symptoms of morning sickness during the first trimester of pregnancy.

Did you know?

Calcitonin is a naturally occurring hormone. In women who are at least 5 years beyond menopause, it slows bone loss and increases spinal bone density.

For a complete list of videos, visit our video library